<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223778</url>
  </required_header>
  <id_info>
    <org_study_id>8591A-017</org_study_id>
    <secondary_id>2019-000586-20</secondary_id>
    <secondary_id>MK-8591A-017</secondary_id>
    <secondary_id>205165</secondary_id>
    <nct_id>NCT04223778</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017))</brief_title>
  <official_title>A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose&#xD;
      combination of doravirine and islatravir) in human immunodeficiency virus -1 (HIV-1)-infected&#xD;
      participants virologically suppressed on a protocol-specified antiretroviral regimen. The&#xD;
      primary hypothesis is that a switch to MK-8591A will be non-inferior to continued treatment&#xD;
      with baseline antiretroviral therapy (ART) as assessed by the proportion of participants with&#xD;
      HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">September 16, 2022</completion_date>
  <primary_completion_date type="Actual">September 8, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with HIV-1 RNA ≥50 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with one or more adverse events (AEs) up to Week 48</measure>
    <time_frame>Day 1 to Week 48</time_frame>
    <description>Percentage of participants with one or more adverse events (AEs) up to Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants who discontinued study intervention up to Week 48</measure>
    <time_frame>Day 1 to Week 48</time_frame>
    <description>Percentage of participants who discontinued study intervention due to an AE up to Week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with HIV-1 RNA &lt;40 or &lt;50 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt;40 or &lt;50 copies/mL at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with HIV-1 RNA ≥50 copies/mL, &lt;40 copies/mL or &lt;50 copies/mL</measure>
    <time_frame>Weeks 48 to 96</time_frame>
    <description>Percentage of participants with HIV-1 RNA ≥50 copies/mL, &lt;40 copies/mL or &lt;50 copies/mL from Week 48 to Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with HIV-1 RNA ≥50 copies/mL, &lt;40 copies/mL or &lt;50 copies/mL</measure>
    <time_frame>Day 1 to Week 96</time_frame>
    <description>Percentage of participants with HIV-1 RNA ≥50 copies/mL, &lt;40 copies/mL or &lt;50 copies/mL from Day 1 to Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell count at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in cluster of differentiation 4+ (CD4+) T-cell count at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4+ T-cell count at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>Change from baseline in CD4+ T-cell count at Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Week 48 in CD4+ T-cell count at Week 96</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Change from Week 48 in CD4+ T-cell count at Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with evidence of viral drug resistance-associated substitutions at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with evidence of viral drug resistance-associated substitutions at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with evidence of viral drug resistance-associated substitutions at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Percentage of participants with evidence of viral drug resistance-associated substitutions at Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting low-density lipoprotein cholesterol and nonhigh- density lipoprotein cholesterol to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in fasting low-density lipoprotein cholesterol and non-high- density lipoprotein cholesterol to Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol to Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in fasting low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol to Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in body weight at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with one or more AEs up to Week 96</measure>
    <time_frame>Day 1 to Week 96</time_frame>
    <description>Percentage of participants with one or more AEs from Day 1 up to Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants who discontinued study intervention up to Week 96</measure>
    <time_frame>Day 1 to Week 96</time_frame>
    <description>Percentage of participants who discontinued study intervention due to an AE from Day 1 up to Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with one or more AEs from Week 48 up to Week 96</measure>
    <time_frame>Weeks 48 to 96</time_frame>
    <description>Percentage of participants with one or more AEs from Week 48 up to Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants who discontinued study intervention from Week 48 up to Week 96</measure>
    <time_frame>Weeks 48 to 96</time_frame>
    <description>Percentage of participants who discontinued study intervention due to an AE from Week 48 up to Week 96</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">672</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Immediate Switch to DOR/ISL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving continuous antiretroviral therapy (ART) will switch to MK-8591A, a fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline Regimen with Delayed Switch to DOR/ISL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving continuous ART for 48 weeks will switch to MK-8591A, a FDC of 100 mg DOR/0.75 mg ISL for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOR/ISL</intervention_name>
    <description>A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily</description>
    <arm_group_label>Baseline Regimen with Delayed Switch to DOR/ISL</arm_group_label>
    <arm_group_label>Immediate Switch to DOR/ISL</arm_group_label>
    <other_name>MK-8591A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is HIV-1 positive&#xD;
&#xD;
          -  Has been receiving continuous, stable oral 2-drug or 3-drug combination (±&#xD;
             pharmacokinetic (PK) booster) with documented viral suppression (HIV-1 RNA &lt;50&#xD;
             copies/mL) for ≥3 months prior to signing informed consent and has no history of prior&#xD;
             virologic treatment failure on any past or current regimen.&#xD;
&#xD;
          -  Female is eligible to participate if she is not pregnant or breastfeeding, and at&#xD;
             least one of the following conditions applies: is not a woman of childbearing&#xD;
             potential (WOCBP); is a WOCBP and using an acceptable contraceptive method, or be&#xD;
             abstinent from heterosexual intercourse as their preferred and usual lifestyle; a&#xD;
             WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as&#xD;
             required by local regulations) within 24 hours before the first dose of study&#xD;
             intervention; if a urine test cannot be confirmed as negative (e.g. an ambiguous&#xD;
             result), a serum pregnancy test is required. In such cases, the participant must be&#xD;
             excluded from participation if the serum pregnancy result is positive;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has HIV-2 infection&#xD;
&#xD;
          -  Has hypersensitivity or other contraindication to any of the components of the study&#xD;
             interventions as determined by the investigator&#xD;
&#xD;
          -  Has an active diagnosis of hepatitis due to any cause, including active Hepatitis B&#xD;
             Virus (HBV) co-infection&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years prior to signing informed consent except for&#xD;
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,&#xD;
             or cutaneous Kaposi's sarcoma&#xD;
&#xD;
          -  Is taking or is anticipated to require systemic immunosuppressive therapy, immune&#xD;
             modulators, or any prohibited therapies&#xD;
&#xD;
          -  Is currently taking long-acting cabotegravir-rilpivirine&#xD;
&#xD;
          -  Is currently participating in or has participated in a clinical study with an&#xD;
             investigational compound or device from 45 days prior to Day 1 through the study&#xD;
             treatment period&#xD;
&#xD;
          -  Has a documented or known virologic resistance to DOR&#xD;
&#xD;
          -  Female expects to conceive or donate eggs at any time during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Hospital ( Site 1018)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research ( Site 1030)</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 1007)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bliss Healthcare Services ( Site 1025)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 1026)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department ( Site 1043)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northstar Healthcare ( Site 1002)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City CARE Health Center ( Site 1008)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Care ( Site 1023)</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill ( Site 1042)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 1038)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 1037)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas ID Consultants, PA ( Site 1003)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Centers for Infectious Disease Associates P.A. ( Site 1022)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, Inc. ( Site 1005)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 2300)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Womens Hospital- Infectious Diseases Unit ( Site 2309)</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Sexual Health Centre ( Site 2305)</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital ( Site 2301)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Alberta HIV Clinic ( Site 1108)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2R 0X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society ( Site 1100)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences ( Site 1103)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maple Leaf Research ( Site 1112)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - University Health Network ( Site 1105)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Medecine Urbaine du Quartier Latin ( Site 1104)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale L Actuel ( Site 1114)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 1305)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Arauco Salud ( Site 1300)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7560994</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica UC CICUC ( Site 1303)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8330034</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 1201)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Francois Mitterrand ( Site 2019)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux- Hopital Saint Andre ( Site 2015)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Purpan ( Site 2004)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu Nantes ( Site 2020)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix-Rousse ( Site 2027)</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-Alpes</state>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen ( Site 2005)</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris, Hopital Saint Louis ( Site 2014)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli-Ospedale Sacco ( Site 2200)</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 2208)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli Instituto di Clinica Chirurgica ( Site 2206)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center ( Site 2403)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital ( Site 2402)</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital ( Site 2406)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital ( Site 2404)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine ( Site 2401)</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital ( Site 2303)</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny SA Przychodnia przy ul. Lowieckiej we Wroclawiu ( Site 1500)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 1503)</name>
      <address>
        <city>Lodz-Baluty</city>
        <state>Lodzkie</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wojewodzki Szpital Zakazny ( Site 1505)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wroclawskie Centrum Zdrowia SP ZOZ ( Site 1507)</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-136</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Center for the Prevention and Control of AIDS ( Site 1713)</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerovskaya Oblast'</state>
        <zip>650056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Center for Prevention and Control of AIDS ( Site 1712)</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnoyarskiy Kray</state>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg Center for Prophylactic of AIDS and Inf. Diseases ( Site 1701)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast'</state>
        <zip>190020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Scientific Methodological AIDS Prevention and Control Center ( Site 1703)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Clinical Hospital #2 ( Site 1719)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 1700)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Center for Prevent. and Control of AIDS and Inf. Diseases ( Site 1715)</name>
      <address>
        <city>Yekaterinburg</city>
        <state>Sverdlovskaya Oblast'</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital of Infectious Diseases n. a. A.F.Agafonov ( Site 1707)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JOSHA Research ( Site 1406)</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation Clinical Trial Unit ( Site 1414)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elche ( Site 1608)</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ( Site 1606)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial ( Site 1600)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon ( Site 1603)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor ( Site 1601)</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz ( Site 1602)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 1604)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel ( Site 3302)</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Universitaetsspital Bern ( Site 3303)</name>
      <address>
        <city>Bern</city>
        <state>Berne</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve HUG. ( Site 3304)</name>
      <address>
        <city>Geneva</city>
        <state>Geneve</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen ( Site 3301)</name>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano Civico ( Site 3305)</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 3300)</name>
      <address>
        <city>Zuerich</city>
        <state>Zurich</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospital NHS Trust ( Site 1908)</name>
      <address>
        <city>Brighton</city>
        <state>Brighton And Hove</state>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital ( Site 1910)</name>
      <address>
        <city>Bristol</city>
        <state>Bristol, City Of</state>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital ( Site 1904)</name>
      <address>
        <city>London</city>
        <state>Camden</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Foundation Trust ( Site 1907)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital ( Site 1902)</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

